Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Nogapendekin alfa by ImmunityBio for Paranasal Sinus And Nasal Cavity Cancer: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer....
CD19 t-haNK by ImmunityBio for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
CD19 t-haNK is under clinical development by ImmunityBio and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...
Nogapendekin alfa by ImmunityBio for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
Nogapendekin alfa by ImmunityBio for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...
Nogapendekin alfa by ImmunityBio for Solid Tumor: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Nogapendekin alfa by ImmunityBio for Hereditary Nonpolyposis Colon Cancer: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Hereditary Nonpolyposis Colon Cancer. According to...
Nogapendekin alfa by ImmunityBio for Metastatic Colorectal Cancer: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
Nogapendekin alfa by ImmunityBio for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...
Nogapendekin alfa by ImmunityBio for Ovarian Cancer: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Nogapendekin alfa by ImmunityBio for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
EEDVD-682 by ImmunityBio for Non-Small Cell Lung Cancer: Likelihood of Approval
EEDVD-682 is under clinical development by ImmunityBio and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
EEDVD-682 by ImmunityBio for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
EEDVD-682 is under clinical development by ImmunityBio and currently in Phase II for Kidney Cancer (Renal Cell Cancer). According to...
EEDVD-682 by ImmunityBio for Solid Tumor: Likelihood of Approval
EEDVD-682 is under clinical development by ImmunityBio and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
EEDVD-682 by ImmunityBio for Bladder Cancer: Likelihood of Approval
EEDVD-682 is under clinical development by ImmunityBio and currently in Phase II for Bladder Cancer. According to GlobalData, Phase II...
EEDVD-682 by ImmunityBio for Head And Neck Cancer: Likelihood of Approval
EEDVD-682 is under clinical development by ImmunityBio and currently in Phase II for Head And Neck Cancer. According to GlobalData,...
EEDVD-682 by ImmunityBio for Melanoma: Likelihood of Approval
EEDVD-682 is under clinical development by ImmunityBio and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs...
EEDVD-682 by ImmunityBio for Colorectal Cancer: Likelihood of Approval
EEDVD-682 is under clinical development by ImmunityBio and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...
EGFR EDV PLK by ImmunityBio for Malignant Mesothelioma: Likelihood of Approval
EGFR EDV PLK is under clinical development by ImmunityBio and currently in Phase I for Malignant Mesothelioma. According to GlobalData,...
EGFR EDV PLK by ImmunityBio for Non-Small Cell Lung Cancer: Likelihood of Approval
EGFR EDV PLK is under clinical development by ImmunityBio and currently in Phase I for Non-Small Cell Lung Cancer. According...
Nogapendekin alfa by ImmunityBio for Pancreatic Cancer: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...